comparemela.com

Latest Breaking News On - Emmanuel papadakis - Page 4 : comparemela.com

NOVARTIS AG : Receives a Buy rating from Deutsche Bank -February 07, 2024 at 06:51 am EST

Emmanuel Papadakis from Deutsche Bank retains his positive opinion on the stock with a Buy rating. The target price is unchanged at CHF 110.

NOVARTIS AG : Deutsche Bank remains its Buy rating -February 02, 2024 at 06:26 am EST

In a research note published by Emmanuel Papadakis, Deutsche Bank advises its customers to buy the stock. The target price remains unchanged at CHF 110.

ROCHE HOLDINGS AG : Receives a Sell rating from Deutsche Bank -February 02, 2024 at 06:30 am EST

In his latest research note, analyst Emmanuel Papadakis confirms his negative recommendation. The broker Deutsche Bank is keeping its Sell rating. The target price is still set at CHF 225.

GSK : Receives a Buy rating from Deutsche Bank -February 01, 2024 at 04:57 am EST

In a research note, Deutsche Bank analyst Emmanuel Papadakis has maintained his recommendation on the stock with a Buy rating. The target price remains set at GBX 1850.

NOVO NORDISK : Deutsche Bank gives a Buy rating -February 01, 2024 at 04:49 am EST

In a research note published by Emmanuel Papadakis, Deutsche Bank advises its customers to buy the stock. Previously set at DKK 850, the target price has been raised to DKK 950.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.